Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Changes
... 15 Artifacts Summary
.... 15.1 AbsenceOfExposureDefinition
.... 15.2 Adaptation
.... 15.3 BaselineMeasureEvidence
.... 15.4 BaselineMeasureReport
.... 15.5 BaselineVariablesList
.... 15.6 BookCitation
.... 15.7 BookPartCitation
.... 15.8 CertaintyOfEvidence
.... 15.9 Classification
.... 15.10 CohortDefinition
.... 15.11 Comment
.... 15.12 ComparativeBaselineMeasureEvidence
.... 15.13 ComparativeEvidence
.... 15.14 ComparativeEvidenceReport
.... 15.15 ComparativeEvidenceReportExpanded
.... 15.16 ComparativeEvidenceReportSubject
.... 15.17 ComparativeEvidenceSynthesisReport
.... 15.18 ComparativeParticipantFlowEvidence
.... 15.19 ComparatorGroup
.... 15.20 ComparatorOnlyEvidence
.... 15.21 Comparison
.... 15.22 CompositeRating
.... 15.23 ConceptualCohortDefinition
.... 15.24 ConceptualComparatorDefinition
.... 15.25 ConceptualExposureDefinition
.... 15.26 DatabaseCitation
.... 15.27 DatabaseEntryCitation
.... 15.28 DatasetCitation
.... 15.29 DateAsRating
.... 15.30 DichotomousIntendedOutcome
.... 15.31 EndpointAnalysisPlan
.... 15.32 EvidenceAssessment
.... 15.33 EvidenceList
.... 15.34 EvidenceReport
.... 15.35 EvidenceReportPackage
.... 15.36 EvidenceReportSubject
.... 15.37 EvidenceSynthesisEvidence
.... 15.38 ExposureGroup
.... 15.39 GroupAssignment
.... 15.40 GroupR6
.... 15.41 Guideline
.... 15.42 InterventionOnlyEvidence
.... 15.43 JournalArticleCitation
.... 15.44 M11ReportContainer
.... 15.45 M11ReportSection01
.... 15.46 M11ReportSection02
.... 15.47 M11ReportSection03
.... 15.48 M11ReportSection04
.... 15.49 M11ReportSection05
.... 15.50 M11ReportSection06
.... 15.51 M11ReportSection07
.... 15.52 M11ReportSection08
.... 15.53 M11ReportSection09
.... 15.54 M11ReportSection10
.... 15.55 M11ReportSection11
.... 15.56 M11ReportSection12
.... 15.57 M11ReportSection13
.... 15.58 M11ReportSection14
.... 15.59 MetaanalysisEligibilityCriteria
.... 15.60 MetaanalysisOutcomeDefinition
.... 15.61 MetaanalysisStudyGroup
.... 15.62 NetEffectContribution
.... 15.63 NetEffectContributionList
.... 15.64 NetEffectContributions
.... 15.65 NetEffectEstimate
.... 15.66 NonComparativeEvidence
.... 15.67 OutcomeDefinition
.... 15.68 OutcomeImportance
.... 15.69 OutcomeList
.... 15.70 OutcomeMeasureReport
.... 15.71 OutcomeVariablesList
.... 15.72 ParticipantFlowEvidence
.... 15.73 ParticipantFlowEvidenceVariable
.... 15.74 ParticipantFlowReasonEvidenceVariable
.... 15.75 ParticipantFlowReport
.... 15.76 ParticipantFlowVariablesList
.... 15.77 PICOSpecification
.... 15.78 PICOTaggedComposition
.... 15.79 PICOTaggedEvidence
.... 15.80 PreprintCitation
.... 15.81 Rating
.... 15.82 Recommendation
.... 15.83 RecommendationAction
.... 15.84 RecommendationEligibilityCriteria
.... 15.85 RecommendationJustification
.... 15.86 RecommendationPlan
.... 15.87 RecommendationRating
.... 15.88 ResearchStudyDataDictionary
.... 15.89 ResearchStudySite
.... 15.90 ResearchStudySupport
.... 15.91 RiskOfBias
.... 15.92 SearchResults
.... 15.93 SearchStrategy
.... 15.94 SingleStudyEvidence
.... 15.95 SoaPlanDefinition
.... 15.96 SoftwareCitation
.... 15.97 StatisticModel
.... 15.98 StudyComponent
.... 15.99 StudyDesign
.... 15.100 StudyEligibilityCriteria
.... 15.101 StudyGroup
.... 15.102 StudyRegistryRecord
.... 15.103 SummaryOfFindings
.... 15.104 SummaryOfNetEffect
.... 15.105 SystematicReview
.... 15.106 SystematicReviewEligibilityCriteria
.... 15.107 SystematicReviewExcludedStudies
.... 15.108 SystematicReviewIncludedStudies
.... 15.109 VariableDefinition
.... 15.110 WebPageCitation
.... 15.111 ArtifactAssessmentCompared
.... 15.112 ArtifactAssessmentDateAsRating
.... 15.113 ArtifactPublicationStatus
.... 15.114 ArtifactRecorder
.... 15.115 CharacteristicTiming
.... 15.116 CiteAs
.... 15.117 EvidenceVariableHandlingDetail
.... 15.118 GuidelineRegistration
.... 15.119 NumberAnalyzed
.... 15.120 RelatesToClassifier
.... 15.121 RelatesToWithQuotation
.... 15.122 RelativeOutcomeImportance
.... 15.123 RelevantForAutomatedMatching
.... 15.124 ResearchStudyExcludedStudy
.... 15.125 ResearchStudyIncludedStudy
.... 15.126 ResearchStudyIsLowInterventionTrial
.... 15.127 ResearchStudyIsRareDisease
.... 15.128 ResearchStudyNumberOfStudiesIdentified
.... 15.129 ResearchStudyNumberOfStudiesIncluded
.... 15.130 ResearchStudySaeReportingMethod
.... 15.131 ResearchStudySearchStrategy
.... 15.132 ResearchStudySponsorConfidentialityStatement
.... 15.133 ResearchStudyStudyAmendment
.... 15.134 ResearchStudySystematicReviewEligibilityCriteria
.... 15.135 StatisticModelExpression
.... 15.136 StatisticModelIncludeIf
.... 15.137 Desirability Codes Value Set
.... 15.138 EBMonFHIR Profile Name Value Set
.... 15.139 Evidence Rating System Classifier Codes Value Set
.... 15.140 PICO Classification Value Set
.... 15.141 Recommendation Justification Classifier Codes Value Set
.... 15.142 Research Study Document Types Value Set
.... 15.143 ResearchStudy Classifier Value Set
.... 15.144 Search Strategy Characteristic Value Set
.... 15.145 Desirability Code System
.... 15.146 EBMonFHIR Profile Name Code System
.... 15.147 Evidence Rating System Classifier Code System
.... 15.148 Research Study Document Types Code System
.... 15.149 Search Strategy Characteristic Code System
.... 15.150 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 15.151 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.152 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 15.153 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 15.154 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 15.155 179899
.... 15.156 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 15.157 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 15.158 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 15.159 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 15.160 19967827 Wonder woman was Argentine and her real name was Evita.
.... 15.161 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 15.162 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 15.163 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 15.164 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 15.165 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 15.166 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 15.167 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 15.168 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 15.169 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 15.170 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 15.171 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 15.172 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 15.173 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 15.174 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 15.175 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 15.176 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 15.177 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 15.178 27979893 6. Glycemic Targets.
.... 15.179 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 15.180 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 15.181 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 15.182 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 15.183 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 15.184 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 15.185 30467172 Finding my inner Wonder Woman.
.... 15.186 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.187 33008778 Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.
.... 15.188 34871555 What Can Wonder Woman Teach Radiologists?
.... 15.189 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 15.190 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 15.191 367832
.... 15.192 367833
.... 15.193 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 15.194 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 15.195 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 15.196 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 15.197 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.198 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.199 Add-on Amlodipine at 6 weeks
.... 15.200 Adults with diabetes mellitus type 2
.... 15.201 Adults with type 2 diabetes and CVD and CKD
.... 15.202 Adults with type 2 diabetes and established CVD (but no CKD)
.... 15.203 Adverse event free and hypertension control
.... 15.204 Adverse event free and hypertension control at 12 weeks
.... 15.205 Adverse Events Report for NCT03421379
.... 15.206 Adverse Events Report for NCT03640312
.... 15.207 Age
.... 15.208 Age with comparator
.... 15.209 Age with intervention
.... 15.210 Aircraft Type
.... 15.211 Aircraft Type with comparator
.... 15.212 Aircraft Type with intervention
.... 15.213 Altitude
.... 15.214 Altitude comparing intervention vs. comparator
.... 15.215 Altitude for enrolled group
.... 15.216 Altitude for screened group
.... 15.217 Altitude with comparator
.... 15.218 Altitude with intervention
.... 15.219 Analyzed Group in PARACHUTE Trial
.... 15.220 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 15.221 Baseline Characteristics Report for NCT03421379
.... 15.222 Baseline Characteristics Report for NCT03640312
.... 15.223 Baseline Characteristics Report for QUARTET Trial
.... 15.224 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.225 Baseline Measures List for PARACHUTE Trial
.... 15.226 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 15.227 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 15.228 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 15.229 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 15.230 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.231 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 15.232 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.233 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.234 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 15.235 Candesartan 8 mg once daily
.... 15.236 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.237 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 15.238 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.239 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.240 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.241 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.242 Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)
.... 15.243 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 15.244 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.245 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.246 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.247 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.248 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.249 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.250 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.251 Citation for EBMonFHIR Implementation Guide
.... 15.252 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.253 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 15.254 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.255 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 15.256 Comparative Evidence Report Expanded for QUARTET USA Trial
.... 15.257 Comparative Evidence Report for QUARTET USA Trial
.... 15.258 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.259 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.260 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.261 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 15.262 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.263 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.264 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.265 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.266 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.267 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 15.268 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 15.269 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 15.270 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 15.271 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 15.272 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 15.273 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 15.274 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 15.275 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 15.276 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 15.277 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 15.278 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 15.279 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 15.280 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 15.281 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 15.282 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.283 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.284 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.285 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.286 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 15.287 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.288 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 15.289 ComparatorDefinition: Standard care
.... 15.290 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.291 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.292 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 15.293 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 15.294 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.295 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.296 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.297 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.298 Composite Rating of FOI 153881 for Project FOI 112280
.... 15.299 Computable_Publishing_LLC
.... 15.300 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 15.301 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.302 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.303 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.304 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.305 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 15.306 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 15.307 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 15.308 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 15.309 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 15.310 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 15.311 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 15.312 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 15.313 ConceptualCohortDefinition: Nonfatal stroke
.... 15.314 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 15.315 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 15.316 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 15.317 ConceptualCohortDefinition: Severe obesity
.... 15.318 ConceptualCohortDefinition: T1DM or T2DM
.... 15.319 ConceptualCohortDefinition: T1DM-specific criteria
.... 15.320 ConceptualCohortDefinition: T2DM-specific criteria
.... 15.321 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 15.322 ConceptualCohortDefinition_Cardiovascular_event
.... 15.323 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.324 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 15.325 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.326 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 15.327 COVID_19PneumoniaHospitalizedAdult
.... 15.328 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.329 CTIS2024-516402-32-00 Eligibility Criteria
.... 15.330 CTIS2024-516402-32-00 Primary Outcome 1
.... 15.331 CTIS2024-516402-32-00 Secondary Outcome 1
.... 15.332 CTIS2024-516402-32-00 Secondary Outcome 2
.... 15.333 CTIS2024-516402-32-00 Secondary Outcome 3
.... 15.334 CTIS2024-516402-32-00 Secondary Outcome 4
.... 15.335 CTIS2024-516402-32-00 Secondary Outcome 5
.... 15.336 CTIS2024-516402-32-00 Secondary Outcome 6
.... 15.337 CTIS2024-516402-32-00 Secondary Outcome 7
.... 15.338 CTIS2024-516402-32-00 Secondary Outcome 8
.... 15.339 DatabaseCitation: Citation for FEvIR Platform
.... 15.340 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.341 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 15.342 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 15.343 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 15.344 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 15.345 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 15.346 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 15.347 declined randomization in PARACHUTE Study
.... 15.348 deemed unsuitable by investigator in PARACHUTE Trial
.... 15.349 Delany-Moretlwe 2022 clinical trial
.... 15.350 Diabetes treatment medication
.... 15.351 Diastolic blood pressure at 12 weeks
.... 15.352 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 15.353 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 15.354 DichotomousIntendedOutcome: New onset depression
.... 15.355 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 15.356 DichotomousIntendedOutcome: Remission of diabetes
.... 15.357 DichotomousIntendedOutcome: Treatment with opioids
.... 15.358 DIO: Mortality
.... 15.359 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 15.360 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 15.361 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 15.362 Eligibility criteria for NMA_Diabetes
.... 15.363 Eligibility Criteria for QUARTET USA Trial
.... 15.364 Enrolled Group for QUARTET USA Trial
.... 15.365 Enrolled Group PARACHUTE Trial
.... 15.366 Ethnic Group
.... 15.367 Ethnic Group with comparator
.... 15.368 Ethnic Group with intervention
.... 15.369 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 15.370 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.371 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 15.372 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 15.373 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.374 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 15.375 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.376 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.377 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.378 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.379 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.380 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 15.381 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.382 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.383 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 15.384 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.385 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.386 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.387 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.388 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 15.389 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.390 EvidenceReportSectionCode Value Set
.... 15.391 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.392 EvidenceVariable Handling Extension Value Set
.... 15.393 EvidenceVariable: case_id
.... 15.394 EvidenceVariable: Patient id
.... 15.395 EvidenceVariable: Time of measurement
.... 15.396 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.397 Excluded from PARACHUTE Study
.... 15.398 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 15.399 ExposureVariable: Age (as continuous variable)
.... 15.400 ExposureVariable: Body Mass Index (as continuous variable)
.... 15.401 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 15.402 ExposureVariable: pht013093.v1.p1 RACE
.... 15.403 ExposureVariable: pht013093.v1.p1 SEX
.... 15.404 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 15.405 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 15.406 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 15.407 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 15.408 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 15.409 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 15.410 ExposureVariable: pht013094.v1.p1 Source_Type
.... 15.411 Family History of Parachute Use
.... 15.412 Family History of Parachute Use with comparator
.... 15.413 Family History of Parachute Use with intervention
.... 15.414 Frequent Flier
.... 15.415 Frequent Flier with comparator
.... 15.416 Frequent Flier with intervention
.... 15.417 GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.418 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 15.419 Glucagon Hydrochloride Solution (Active Comparator)
.... 15.420 Glucagon Nasal Powder (Experimental)
.... 15.421 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 15.422 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 15.423 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 15.424 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.425 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.426 GroupAssignment: GLP-1 RA vs. Standard care
.... 15.427 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 15.428 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 15.429 GroupAssignment: Non Participants vs. Enrolled Participants
.... 15.430 GroupAssignment: Quadpill vs. Candesartan
.... 15.431 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 15.432 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 15.433 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 15.434 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 15.435 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 15.436 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.437 Health Survey Score Total
.... 15.438 Health Survey Score Total comparing intervention vs. comparator
.... 15.439 Health Survey Score Total with comparator
.... 15.440 Health Survey Score Total with intervention
.... 15.441 Health Survey Score-Mental Health Subscore
.... 15.442 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 15.443 Health Survey Score-Mental Health Subscore with comparator
.... 15.444 Health Survey Score-Mental Health Subscore with intervention
.... 15.445 Health Survey Score-Physical Health Subscore
.... 15.446 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 15.447 Health Survey Score-Physical Health Subscore with comparator
.... 15.448 Health Survey Score-Physical Health Subscore with intervention
.... 15.449 Health-related Quality of Life (Mental) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.450 Health-related Quality of Life (NCT03640312)
.... 15.451 Health-related Quality of Life (Physical) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.452 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 15.453 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.454 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.455 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 15.456 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.457 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.458 Height
.... 15.459 Height with comparator
.... 15.460 Height with intervention
.... 15.461 High Blood Pressure Medication Value Set
.... 15.462 History of Acrophobia
.... 15.463 History of Acrophobia with comparator
.... 15.464 History of Acrophobia with intervention
.... 15.465 History of Broken Bones
.... 15.466 History of Broken Bones with comparator
.... 15.467 History of Broken Bones with intervention
.... 15.468 History of Parachute Use
.... 15.469 History of Parachute Use with comparator
.... 15.470 History of Parachute Use with intervention
.... 15.471 Hypertension Control at 12 weeks
.... 15.472 ICD-10-GM Terminale Codes
.... 15.473 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 15.474 Injury Severity Score 30 days after Impact with comparator
.... 15.475 Injury Severity Score 30 days after Impact with intervention
.... 15.476 Injury Severity Score on Impact comparing intervention vs. comparator
.... 15.477 Injury Severity Score on Impact with comparator
.... 15.478 Injury Severity Score on Impact with intervention
.... 15.479 International vs Domestic Flight
.... 15.480 International vs Domestic Flight with comparator
.... 15.481 International vs Domestic Flight with intervention
.... 15.482 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.483 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 15.484 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.485 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.486 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.487 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.488 Investigator
.... 15.489 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 15.490 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 15.491 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.492 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.493 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.494 Jumping from aircraft with empty backpack
.... 15.495 Jumping from aircraft with parachute
.... 15.496 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.497 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.498 M11 IGBJ Protocol Example Eligibility Criteria
.... 15.499 M11 Report for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.500 M11 Report for M11ResearchStudy Template
.... 15.501 M11 Report Section 1 (Protocol Summary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.502 M11 Report Section 1 (Protocol Summary) for M11ResearchStudy Template
.... 15.503 M11 Report Section 10 (Statistical Considerations) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.504 M11 Report Section 10 (Statistical Considerations) for M11ResearchStudy Template
.... 15.505 M11 Report Section 11 (Trial Oversight) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.506 M11 Report Section 11 (Trial Oversight) for M11ResearchStudy Template
.... 15.507 M11 Report Section 12 (Supporting Details) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.508 M11 Report Section 12 (Supporting Details) for M11ResearchStudy Template
.... 15.509 M11 Report Section 13 (Glossary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.510 M11 Report Section 13 (Glossary) for M11ResearchStudy Template
.... 15.511 M11 Report Section 14 (References) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.512 M11 Report Section 14 (References) for M11ResearchStudy Template
.... 15.513 M11 Report Section 2 (Introduction) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.514 M11 Report Section 2 (Introduction) for M11ResearchStudy Template
.... 15.515 M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.516 M11 Report Section 3 (Trial Objectives and Associated Estimands) for M11ResearchStudy Template
.... 15.517 M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.518 M11 Report Section 4 (Trial Design) for M11ResearchStudy Template
.... 15.519 M11 Report Section 5 (Trial Population) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.520 M11 Report Section 5 (Trial Population) for M11ResearchStudy Template
.... 15.521 M11 Report Section 6 (Trial Intervention) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.522 M11 Report Section 6 (Trial Intervention) for M11ResearchStudy Template
.... 15.523 M11 Report Section 7 (Participant Discontinuation) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.524 M11 Report Section 7 (Participant Discontinuation) for M11ResearchStudy Template
.... 15.525 M11 Report Section 8 (Trial Assessments) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.526 M11 Report Section 8 (Trial Assessments) for M11ResearchStudy Template
.... 15.527 M11 Report Section 9 (Adverse Events) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.528 M11 Report Section 9 (Adverse Events) for M11ResearchStudy Template
.... 15.529 M11ResearchStudy Template
.... 15.530 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.531 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.532 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.533 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.534 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.535 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.536 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.537 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.538 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.539 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.540 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.541 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.542 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.543 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.544 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.545 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.546 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.547 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.548 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.549 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.550 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.551 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.552 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.553 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.554 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.555 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.556 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.557 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.558 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.559 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.560 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.561 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.562 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.563 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.564 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.565 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.566 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.567 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.568 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.569 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.570 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.571 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.572 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.573 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.574 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.575 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.576 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.577 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.578 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.579 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.580 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.581 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.582 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.583 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.584 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.585 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.586 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.587 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.588 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.589 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.590 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.591 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.592 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.593 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.594 MAGICapp-derived Group: GLP-1 RA Group in Adults with type 2 diabetes
.... 15.595 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 15.596 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 15.597 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.598 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.599 Mean Change in Serum Creatinine (NCT03640312)
.... 15.600 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 15.601 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.602 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.603 Mean Change in Serum Potassium (NCT03640312)
.... 15.604 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 15.605 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.606 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.607 Mean Change in Serum Sodium (NCT03640312)
.... 15.608 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 15.609 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.610 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.611 Mean Diastolic Blood Pressure (NCT03640312)
.... 15.612 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.613 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.614 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.615 Mean Systolic Blood Pressure (NCT03640312)
.... 15.616 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.617 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.618 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.619 Median Age of Parachute Intervention Group
.... 15.620 Medication Adherence (NCT03640312)
.... 15.621 Medication Adherence at 12 weeks
.... 15.622 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 15.623 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.624 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.625 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.626 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.627 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 15.628 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.629 Mortality at 14 days
.... 15.630 NCT03421379 Eligibility Criteria
.... 15.631 NCT03640312 Eligibility Criteria
.... 15.632 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.633 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.634 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.635 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.636 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.637 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.638 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 15.639 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 15.640 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.641 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 15.642 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 15.643 NHANES LBXGLU Variable Definition Cohort Definition
.... 15.644 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 15.645 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 15.646 NHANES SEQN Respondent Sequence Number
.... 15.647 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 15.648 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 15.649 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 15.650 NT-proBNP Study Data Dictionary
.... 15.651 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 15.652 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 15.653 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.654 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.655 Organ support-free days
.... 15.656 Outcome Importance Rating 100 of All-cause mortality
.... 15.657 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 15.658 Outcome Importance Rating 5 of New onset depression
.... 15.659 Outcome Importance Rating 5 of Remission of diabetes
.... 15.660 Outcome Importance Rating 5 of Treatment with opioids
.... 15.661 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 15.662 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.663 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.664 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.665 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.666 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.667 Outcome Importance Rating of Mortality for Bariatric Surgery Patients
.... 15.668 Outcome Measure List for QUARTET USA Trial
.... 15.669 Outcome Measure Report for QUARTET USA Trial
.... 15.670 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.671 Outcome Measures Report for NCT03421379
.... 15.672 Outcome Measures Report for NCT03640312
.... 15.673 Outcome Variables List for PARACHUTE Trial
.... 15.674 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 15.675 Outcome: Death or Major Traumatic Injury on Impact
.... 15.676 Outcome: Injury Severity Score 30 days after Impact
.... 15.677 Outcome: Injury Severity Score on Impact
.... 15.678 OutcomeDefinition for All-cause mortality
.... 15.679 OutcomeDefinition for Body weight
.... 15.680 OutcomeDefinition for Cardiovascular mortality
.... 15.681 OutcomeDefinition for Diabetic ketoacidosis
.... 15.682 OutcomeDefinition for End-stage kidney disease
.... 15.683 OutcomeDefinition for Genital infection
.... 15.684 OutcomeDefinition for Health-related quality of life
.... 15.685 OutcomeDefinition for Heart failure
.... 15.686 OutcomeDefinition for Nonfatal myocardial infarction
.... 15.687 OutcomeDefinition for Nonfatal stroke
.... 15.688 OutcomeDefinition for Serious hyperglycaemia
.... 15.689 OutcomeDefinition for Severe gastrointestinal events
.... 15.690 OutcomeDefinition: Injury Severity Score on Impact
.... 15.691 OutcomeDefinition: All-cause mortality
.... 15.692 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 15.693 OutcomeDefinition: Body weight
.... 15.694 OutcomeDefinition: Cardiovascular mortality
.... 15.695 OutcomeDefinition: Diabetes in remission
.... 15.696 OutcomeDefinition: End-stage kidney disease
.... 15.697 OutcomeDefinition: HbA1c at 12 months
.... 15.698 OutcomeDefinition: HbA1c at 24 months
.... 15.699 OutcomeDefinition: HbA1c at 36 months
.... 15.700 OutcomeDefinition: HbA1c at 6 months
.... 15.701 OutcomeDefinition: HbA1c at 60 months
.... 15.702 OutcomeDefinition: Health-related quality of life
.... 15.703 OutcomeDefinition: Heart failure
.... 15.704 OutcomeDefinition: Mortality at 14 days
.... 15.705 OutcomeDefinition: New onset depression
.... 15.706 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.707 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 15.708 OutcomeDefinition: Nonfatal stroke
.... 15.709 OutcomeDefinition: Serious hyperglycaemia
.... 15.710 OutcomeDefinition: Severe gastrointestinal events
.... 15.711 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.712 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.713 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 15.714 OutcomeVariable: HbA1c at 12 months
.... 15.715 OutcomeVariable: HbA1c at 24 months
.... 15.716 OutcomeVariable: HbA1c at 36 months
.... 15.717 OutcomeVariable: HbA1c at 6 months
.... 15.718 OutcomeVariable: HbA1c at 60 months
.... 15.719 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.720 OutcomeVariable: New onset depression
.... 15.721 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 15.722 OutcomeVariable: Remission of diabetes
.... 15.723 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.724 OutcomeVariable_Additional_GI_surgical_procedure
.... 15.725 OutcomeVariable_All_cause_mortality
.... 15.726 OutcomeVariable_Treatment_with_opioids
.... 15.727 PARACHUTE Trial baseline characteristics
.... 15.728 PARACHUTE Trial non participants
.... 15.729 PARACHUTE trial participant flow report
.... 15.730 PARACHUTE Trial Participants
.... 15.731 PARACHUTE Trial Participants assigned an empty backpack
.... 15.732 PARACHUTE trial participants assigned parachute
.... 15.733 PARACHUTE Trial Participants available for randomization
.... 15.734 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 15.735 PARACHUTE Trial Participants randomized into groups
.... 15.736 PARACHUTE Trial Participants randomized into groups for screened group
.... 15.737 PARACHUTE Trial Participants randomized into groups with comparator
.... 15.738 PARACHUTE Trial Participants randomized into groups with intervention
.... 15.739 PARACHUTE Trial Participants that completed 30 day follow up
.... 15.740 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 15.741 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 15.742 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 15.743 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 15.744 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 15.745 PARACHUTE Trial Participants that declined randomization
.... 15.746 PARACHUTE Trial Participants with no contact at 30 days
.... 15.747 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 15.748 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 15.749 PARACHUTE Trial Results
.... 15.750 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.751 Parachute vs Empty Backpack in PARACHUTE Trial
.... 15.752 Participant Flow Report for NCT03421379
.... 15.753 Participant Flow Report for NCT03640312
.... 15.754 Participant Flow Report for QUARTET USA Trial
.... 15.755 Participant Flow Variables List for PARACHUTE Trial
.... 15.756 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 15.757 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 15.758 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 15.759 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 15.760 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 15.761 ParticipantFlowMeasure: Exclusion from analysis
.... 15.762 ParticipantFlowMeasure: Inclusion in analysis
.... 15.763 Participants Excluded from PARACHUTE Study
.... 15.764 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 15.765 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 15.766 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.767 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.768 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.769 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 15.770 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.771 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.772 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 15.773 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 15.774 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 15.775 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.776 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.777 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 15.778 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 15.779 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.780 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.781 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 15.782 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.783 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.784 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.785 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.786 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.787 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.788 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.789 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.790 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.791 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.792 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.793 Placebo
.... 15.794 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.795 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.796 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 15.797 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 15.798 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 15.799 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.800 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.801 Proportion of Patients With Hypertension Control (NCT03640312)
.... 15.802 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 15.803 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 15.804 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 15.805 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 15.806 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 15.807 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 15.808 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.809 Quadpill once daily
.... 15.810 QUARTET USA Trial Control Group
.... 15.811 QUARTET USA Trial Quadpill group
.... 15.812 randomized into groups for PARACHUTE Trial
.... 15.813 Rate of Adverse Events of Special Interest (NCT03640312)
.... 15.814 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 15.815 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.816 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.817 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 15.818 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 15.819 Reasons for exclusion from QUARTET USA Trial
.... 15.820 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 15.821 Recommendation Justification Code System
.... 15.822 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 15.823 Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.824 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 15.825 Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.826 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 15.827 Remdesivir
.... 15.828 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 15.829 ResearchStudy Classifier Code System
.... 15.830 Results Section for NCT03421379
.... 15.831 Results Section for NCT03640312
.... 15.832 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.833 Risk of Bias Assessment of PARACHUTE trial
.... 15.834 Risk Of Bias Type Value Set
.... 15.835 Screened Group PARACHUTE Trial
.... 15.836 Search Strategy for NMA_Diabetes
.... 15.837 SearchResults: PubMed search for Wonder Woman
.... 15.838 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 15.839 SearchStrategy: PubMed search for Wonder Woman
.... 15.840 Sex
.... 15.841 Sex with comparator
.... 15.842 Sex with intervention
.... 15.843 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.844 SMR-excluded Tlayjeh H J Infect Public Health 33008778
.... 15.845 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 15.846 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 15.847 Spanish or English Value Set
.... 15.848 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.849 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 15.850 StudyEligibilityCriteria for M11Report Example
.... 15.851 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 15.852 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 15.853 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.854 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 15.855 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 15.856 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 15.857 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 15.858 Summary of Findings - QUARTET USA Trial
.... 15.859 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 15.860 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.861 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.862 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.863 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.864 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.865 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.866 Systolic blood pressure at 12 weeks
.... 15.867 Time to integration of results in a recommendation
.... 15.868 VariableDefinition: Comparator
.... 15.869 VariableDefinition: Condition(s)
.... 15.870 VariableDefinition: Date of birth
.... 15.871 VariableDefinition: Date of measurement
.... 15.872 VariableDefinition: Gender
.... 15.873 VariableDefinition: NTproBNP
.... 15.874 VariableDefinition: Unit
.... 15.875 Velocity
.... 15.876 Velocity comparing intervention vs. comparator
.... 15.877 Velocity for enrolled group
.... 15.878 Velocity for non participant group
.... 15.879 Velocity with comparator
.... 15.880 Velocity with intervention
.... 15.881 WebPageCitation: A HEvKA Update Summary
.... 15.882 Weight
.... 15.883 Weight with comparator
.... 15.884 Weight with intervention